Case Study

Read how we helped a major player in the neurology market develop priorities for resource allocation in order to maximise the value of the neurology portfolio.
Read the case study...

Catenion's R&D Suite of Tools, Processes and Methods for Asset Valuation

R&D Risk Assessment: An expert system with more than 600 criteria measuring a project's risk level against industry average, differentiated by drug format (small molecules, biologics, monoclonal antibodies, etc) and stage of the R&D process. Based on the input of hundreds of industry experts and used to evaluate more than 600 projects to date.

Option Space Mapping: A systematic approach to map out the development options of a project based on hard biological, chemical, and pre–clinical data regarding target and own compound, competitor compounds, market situation and the project´s position in pipeline.

Innovativeness Screening: A method developed to assess market attractiveness for early compounds before proof of concept and used instead of more elaborate forecasting methods. Key dimensions are novelty, usefulness, theoretical market potential and exploitability by company.

Competitiveness Modeling: An elaborate forecasting tool developed by Catenion for post–proof–of–concept compounds. The tool permits rating of product features against those of current and expected competitors and forecasts the whole market, rather than just one company’s compound.